Form 4: AngioDynamics CEO James Clemmer Buys 20,000 Shares
SEC Form 4 Filing
AngioDynamics' CEO, James C. Clemmer, recently acquired 20,000 shares of the company's common stock at an average price of $6.03 per share.
Summary
- On October 7, 2024, James C. Clemmer, the President and CEO of AngioDynamics Inc., purchased 20,000 shares of the company's common stock.
- The shares were bought at a weighted average price of $6.03, with individual transactions ranging from $5.95 to $6.08.
- Following this transaction, Clemmer directly owns 681,582 shares of AngioDynamics.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive signal, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about his confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor among many to consider when evaluating a company's potential.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/07/2024 | Date of the transaction: James C. Clemmer purchased 20,000 shares of AngioDynamics stock. |
| 10/08/2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.